India, July 23 -- Samsung Biologics (207940.KS) reported operating profit of 475.6 billion South Korean won in the second quarter of 2025, up from 434.5 billion won last year. Consolidated revenue rose to 1.290 trillion won from 1.157 trillion won in the previous year.
On a standalone basis, the company reported revenue of 1.014 trillion won and operating profit of 477.0 billion won in the second quarter of 2025.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....